• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Influence of physician networks on prescribing a new ingredient combination in heart failure: a longitudinal claim data-based study.医生网络对心力衰竭新配方药物处方的影响:一项基于纵向索赔数据的研究。
Implement Sci. 2021 Aug 28;16(1):84. doi: 10.1186/s13012-021-01150-y.
2
Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.沙库巴曲缬沙坦与射血分数降低的心力衰竭患者健康状况结局的相关性。
JACC Heart Fail. 2019 Nov;7(11):933-941. doi: 10.1016/j.jchf.2019.05.016. Epub 2019 Sep 11.
3
Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure.指南发布对心力衰竭住院患者使用血管紧张素受体脑啡肽酶抑制剂的早期影响。
Am Heart J. 2018 Jun;200:134-140. doi: 10.1016/j.ahj.2018.01.009. Epub 2018 Jan 31.
4
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.射血分数对沙库巴曲缬沙坦(LCZ696)治疗射血分数降低的心力衰竭的疗效及预后的影响:ARNI与ACEI对心力衰竭全球死亡率和发病率影响的前瞻性比较(PARADIGM-HF)试验
Circ Heart Fail. 2016 Mar;9(3):e002744. doi: 10.1161/CIRCHEARTFAILURE.115.002744.
5
Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).沙库巴曲缬沙坦在射血分数降低的心力衰竭患者中的早期应用:来自“遵循指南-心力衰竭(GWTG-HF)”的见解。
JACC Heart Fail. 2017 Apr;5(4):305-309. doi: 10.1016/j.jchf.2016.12.018.
6
The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.沙库巴曲缬沙坦,全球首创的血管紧张素受体脑啡肽酶抑制剂(ARNI):在高血压、心力衰竭及其他领域的潜在应用。
Curr Cardiol Rep. 2018 Jan 27;20(1):5. doi: 10.1007/s11886-018-0944-4.
7
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.血管紧张素受体-脑啡肽酶抑制剂与标准治疗相比用于射血分数降低的心力衰竭患者的估计 5 年治疗需要人数,以预防心血管死亡或心力衰竭住院:来自 PARADIGM-HF 试验的数据分析。
JAMA Cardiol. 2018 Dec 1;3(12):1226-1231. doi: 10.1001/jamacardio.2018.3957.
8
Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.血管紧张素受体脑啡肽酶抑制剂用于射血分数降低的心力衰竭患者:来自台湾的真实世界经验
J Cardiovasc Pharmacol Ther. 2020 Mar;25(2):152-157. doi: 10.1177/1074248419872958. Epub 2019 Sep 12.
9
Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.将射血分数降低的心力衰竭患者转换为沙库巴曲缬沙坦治疗的成本效益:澳大利亚视角
Heart Lung Circ. 2020 Sep;29(9):1310-1317. doi: 10.1016/j.hlc.2019.03.007. Epub 2019 Apr 2.
10
Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis.泰国血管紧张素受体/脑啡肽酶抑制剂(ARNI)应用的真实世界经验:单中心回顾性分析。
BMC Cardiovasc Disord. 2021 Jul 2;21(1):324. doi: 10.1186/s12872-021-02145-9.

引用本文的文献

1
The association of prescriber prominence in a shared-patient physician network with their patients receipt of and transitions between risky drug combinations.在共享患者的医生网络中,开处方者的知名度与其患者接受高风险药物组合以及在高风险药物组合之间转换的情况之间的关联。
Appl Netw Sci. 2025;10(1):34. doi: 10.1007/s41109-025-00721-y. Epub 2025 Jul 21.
2
Identifying opioid agonist treatment prescriber networks from health administrative data: A validation study.从卫生行政数据中识别阿片类激动剂治疗处方医生网络:一项验证研究。
PLoS One. 2025 May 16;20(5):e0322064. doi: 10.1371/journal.pone.0322064. eCollection 2025.
3
A Scoping Review of Multilevel Patient-Sharing Network Measures in Health Services Research.卫生服务研究中多层次患者共享网络措施的范围综述
Med Care Res Rev. 2025 Jun;82(3):203-224. doi: 10.1177/10775587241304140. Epub 2024 Dec 30.
4
Evidence-informed language: interpretation and impact on intentions to treat - results of an online survey of medical students and specialists in German-speaking countries.循证语言:解释及其对治疗意向的影响——对德语国家医学生和专家的在线调查结果
BMJ Open. 2025 Feb 7;15(2):e082907. doi: 10.1136/bmjopen-2023-082907.
5
Exploiting relationship directionality to enhance statistical modeling of peer-influence across social networks.利用关系方向性来增强社交网络中同伴影响的统计建模。
Stat Med. 2024 Sep 20;43(21):4073-4097. doi: 10.1002/sim.10169. Epub 2024 Jul 9.
6
Influence of physician networks on the implementation of pharmaceutical alternatives to a toxic drug supply in British Columbia.医师网络对不列颠哥伦比亚省有毒药品供应替代药品实施的影响。
Implement Sci. 2024 Jan 6;19(1):3. doi: 10.1186/s13012-023-01331-x.
7
Influence of Cooperation Work on Management Continuity of Ambulatory Cardiovascular Care: A Cross-Sectional Exploratory Study in Germany.合作工作对门诊心血管护理管理连续性的影响:德国的一项横断面探索性研究。
Int J Integr Care. 2023 Dec 6;23(4):14. doi: 10.5334/ijic.7019. eCollection 2023 Oct-Dec.
8
Can peer effects explain prescribing appropriateness? a social network analysis.同伴效应能否解释处方的适宜性?一项社会网络分析。
BMC Med Res Methodol. 2023 Oct 28;23(1):252. doi: 10.1186/s12874-023-02048-7.
9
Health workers' social networks and their influence in the adoption of strategies to address the stillbirth burden at a subnational level health system in Uganda.卫生工作者的社会网络及其在乌干达一个次国家级卫生系统中采用应对死产负担策略方面的影响。
PLOS Glob Public Health. 2022 Jul 25;2(7):e0000798. doi: 10.1371/journal.pgph.0000798. eCollection 2022.

本文引用的文献

1
Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants.沙库巴曲缬沙坦在瑞典的应用:临床特征、滴定模式及影响因素
ESC Heart Fail. 2020 Dec;7(6):3633-3643. doi: 10.1002/ehf2.12883. Epub 2020 Sep 3.
2
Prescribing and medical non-adherence after myocardial infarction: qualitative interviews with general practitioners in Germany.心肌梗死后的处方和医疗不依从:德国全科医生的定性访谈。
BMC Fam Pract. 2020 May 8;21(1):81. doi: 10.1186/s12875-020-01145-6.
3
Promoting rational antibiotic prescribing for non-complicated infections: understanding social influence in primary care networks in Germany.促进非复杂性感染的合理抗生素处方:了解德国初级保健网络中的社会影响。
BMC Fam Pract. 2020 Mar 14;21(1):51. doi: 10.1186/s12875-020-01119-8.
4
Diffusion/Contagion Processes on Social Networks.社交网络上的扩散/传染过程。
Health Educ Behav. 2020 Apr;47(2):235-248. doi: 10.1177/1090198120901497. Epub 2020 Feb 24.
5
Local opinion leaders: effects on professional practice and healthcare outcomes.当地意见领袖:对专业实践和医疗结果的影响。
Cochrane Database Syst Rev. 2019 Jun 24;6(6):CD000125. doi: 10.1002/14651858.CD000125.pub5.
6
Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany.沙库巴曲缬沙坦的真实世界治疗模式:德国的一项纵向队列研究。
Eur J Heart Fail. 2019 May;21(5):588-597. doi: 10.1002/ejhf.1465. Epub 2019 Apr 11.
7
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.与美国沙库巴曲缬沙坦使用相关的患者、提供者和实践特征。
Circ Heart Fail. 2018 Sep;11(9):e005400. doi: 10.1161/CIRCHEARTFAILURE.118.005400.
8
Influence of peer networks on physician adoption of new drugs.同伴网络对医生采用新药的影响。
PLoS One. 2018 Oct 1;13(10):e0204826. doi: 10.1371/journal.pone.0204826. eCollection 2018.
9
A scoping review of patient-sharing network studies using administrative data.利用行政数据进行患者共享网络研究的范围综述。
Transl Behav Med. 2018 Jul 17;8(4):598-625. doi: 10.1093/tbm/ibx015.
10
Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.沙库巴曲缬沙坦在心力衰竭管理中的应用。
Circ Heart Fail. 2018 Feb;11(2):e004302. doi: 10.1161/CIRCHEARTFAILURE.117.004302.

医生网络对心力衰竭新配方药物处方的影响:一项基于纵向索赔数据的研究。

Influence of physician networks on prescribing a new ingredient combination in heart failure: a longitudinal claim data-based study.

机构信息

Department of General Practice and Health Services Research, Heidelberg University Hospital, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany.

出版信息

Implement Sci. 2021 Aug 28;16(1):84. doi: 10.1186/s13012-021-01150-y.

DOI:10.1186/s13012-021-01150-y
PMID:34454547
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8401102/
Abstract

BACKGROUND

Since 2016, the combination of sacubitril/valsartan, which combines an angiotensin receptor and neprilysin inhibitor (ARNI), has been recommended in the guidelines for the treatment of heart failure. The adoption of new drugs may be influenced by collaboration and exchange between physicians. We aimed to determine whether characteristics of the professional networks of prescribing physicians were associated with the prescribing of ARNI in Germany.

METHODS

We conducted a longitudinal analysis based on claims data in 2016-2018 in Germany. The characteristics of ambulatory care physicians' networks were determined in the analysis of the patient-sharing networks of physicians in 2017. Binary logistic regression analysis with the outcome 'prescribes ARNI in 2018' (present or absent) was carried out, using network characteristics as predictors, adjusted for specialty and sociodemographic characteristics of physicians.

RESULTS

The network analysis included 8370 physicians, who had 144,636 connections. Prescribers had more connections to other physicians compared to non-prescribers (median 31 vs. 23). Regression analysis showed that the numbers of linkages to prescribers of ARNI were positively associated with prescribing ARNI. For 6-10 connections, the average marginal effect (AME) was 0.04 (confidence interval [CI] 95% 0.01-0.06) and for > 10 links the AME 0.07 (CI 95% 0.05-0.10) compared to 0-5 connections to prescriber.

CONCLUSION

Physicians who shared patients with many other physicians were more likely to prescribe ARNI, independent of physicians' specialty. This suggested that collaboration and exchange on the basis of patient-sharing with other physicians influenced their medication prescribing decisions.

摘要

背景

自 2016 年以来,血管紧张素受体和脑啡肽酶抑制剂(ARNI)的组合沙库巴曲缬沙坦已被推荐用于心力衰竭的治疗指南。新药的采用可能受到医生之间合作和交流的影响。我们旨在确定开处方医生的专业网络特征是否与德国 ARNI 的处方有关。

方法

我们基于德国 2016-2018 年的索赔数据进行了纵向分析。在 2017 年对医生的患者共享网络进行分析时,确定了门诊医生网络的特征。使用二元逻辑回归分析,以“2018 年处方 ARNI”(存在或不存在)作为结果,将网络特征作为预测因素进行分析,调整了医生的专业和社会人口统计学特征。

结果

网络分析包括 8370 名医生,他们有 144636 个联系。与非处方医生相比,处方医生与其他医生的联系更多(中位数 31 对 23)。回归分析表明,与 ARNI 处方医生的联系数量与处方 ARNI 呈正相关。对于 6-10 个联系,平均边际效应(AME)为 0.04(95%置信区间 [CI] 0.01-0.06),对于 >10 个联系,AME 为 0.07(95%CI 0.05-0.10)与 0-5 个与处方医生的联系相比。

结论

与许多其他医生共享患者的医生更有可能开 ARNI,而与医生的专业无关。这表明,基于与其他医生的患者共享进行合作和交流会影响他们的药物处方决策。